Regulation of different inflammatory diseases by impacting the mevalonate pathway

Immunology

Volumn 127, Issue 1, 2009, Pages 18-25

  Zeiser, Robert ^a   Maas, Kristina ^a   Youssef, Sawsan ^b   Dürr, Christoph ^a   Steinman, Lawrence ^b   Negrin, Robert S ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Graft versus host disease; Mevalonate pathway; Statins; T cell responses

Indexed keywords

ALLOANTIGEN; ATORVASTATIN; AUTOANTIGEN; C REACTIVE PROTEIN; CHLOROQUINE; COMPACTIN; CYTOKINE; FLUINDOSTATIN; GERANYLGERANYL TRANSFERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SIMVASTATIN; TRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DISEASE MODEL; DISEASE SEVERITY; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART PROTECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH2 CELL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; MEVALONIC ACID; SIGNAL TRANSDUCTION;

EID: 63849284084     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.03011.x     Document Type: Review

References (65)

1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 101 : 207 13.
2. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 420 : 78 84.
3. Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003 197 : 725 33.
4. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006 203 : 401 12.
5. Zipp F, Waiczies S, Aktas O et al. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007 28 : 342 9.
6. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand Black/White F1 mice. J Immunol 2004 173 : 7641 6.
7. Zeiser R, Youssef S, Baker J, Kambhan N, Steinman L, Negrin RS. HMG-CoA reductase inhibitors (statins) provide acute-graft-versus-host disease protection by Th2 cytokine induction while sparing graft-versus-leukemia activity. Blood 2007 110 : 4588 98.
8. Raki M, Molberg O, Tollefsen S, Lundin KE, Sollid LM. The effects of atorvastatin on gluten-induced intestinal T cell responses in coeliac disease. Clin Exp Immunol 2005 142 : 333 40.
9. Waiczies S, Prozorovski T, Infante-Duarte C et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 2005 74 : 5630 5.
10. + T cells. Atherosclerosis 2008 197 : 829 39.
11. Broz P, Ben-Haim N, Grzelakowski M, Marsch S, Meier W, Hunziker P. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin. J Cardiovasc Pharmacol 2008 51 : 246 52.
12. Yilmaz A, Reiss C, Tantawi O et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004 172 : 85 93.
13. Xu SZ, Zhong W, Watson NM, Dickerson E, Wake JD, Lindow SW, Newton CJ, Atkin SL. Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. J Thromb Haemost 2008 4 : 692 700.
14. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000 6 : 1399 402.
15. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003 17 : 905 7.
16. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003 170 : 1524 30.
17. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004 363 : 1607 8.
18. Paul F, Waiczies S, Wuerfel J et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008 3 : 1928.
19. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004 363 : 2015 21.
20. Hori A, Kanda Y, Goyama S et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005 79 : 372 4.
21. Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum 2008 58 : 2098 104.
22. Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato I. Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007 46 : 1560 5.
23. Kotyla PJ. Comment on: atorvastatin therapy improves endothelial- dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial. Rheumatology 2008 47 : 381 2.
24. Mason JC. Statins and their role in vascular protection. Clin Sci 2003 105 : 251 66.
25. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune disease? Clin Rev Allerg Immunol 2002 23 : 263 77.
26. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, González-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003 12 : 607 11.
27. Kanda H, Yokota K, Kohno C et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol 2007 17 : 364 8.
28. Lazzerini PE, Lorenzini S, Selvi E et al. Simvastatin inhibits cytokine production and NF-κB activation in IL-1β-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 2007 25 : 696 700.
29. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 6 : 1167 75.
30. Hafler DA. Multiple sclerosis. J Clin Invest 2004 113 : 788 94.
31. Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004 172 : 1273 86.
32. Stüve O, Youssef S, Weber MS et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 2006 116 : 1037 44.
33. + lymphocytes. J Immunol 2008 180 : 6988 96.
34. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002 8 : 500 8.
35. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 : 39 42.
36. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995 333 : 621 7.
37. Kobashigawa JA, Moriguchi JD, Laks H et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005 24 : 1736 43.
38. Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001 38 : 814 21.
39. Holschermann H, Hilgendorff A, Kemkes-Matthes B et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000 69 : 1830 9.
40. Zhang W, Liu M, Wu Y, Zhu P, Yin C, Zhang W, Gu M. Protective effects of atorvastatin on chronic allograft nephropathy in rats. J Surg Res 2007 143 : 428 36.
41. Li C, Yang CW, Park JH et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004 286 : 46 53.
42. Liu M, Wu YC, Zhang W et al. Effect of atorvastatin on intrarenal osteopontin expression in rat allogeneic kidney transplantation. Chin J Clin Rehab 2006 62 : 1651 8.
43. Langham RG, Egan MK, Dowling JP et al. Transforming growth factor-beta1 and TGF-β-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 2001 72 : 1826 32.
44. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996 4 : 313 9.
45. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008 111 : 3901 2.
46. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995 15 : 825 8.
47. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 2008 79 : 14 23.
48. Zeiser R, Albrecht-Bellingrath W, Schaefer HE. Age-dependent leiomuscular atrophy in vertebral arteries of individuals under low fat diet. In Vivo 2000 14 : 631 4.
49. Bis JC, Heckbert SR, Smith NL et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 2008 198 : 166 73.
50. Eccles KA, Sowden H, Porter KE, Parkin SM, Homer-Vanniasinkam S, Graham AM. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008 200 : 69 79.
51. Park SY, Lee JS, Ko YJ et al. Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation. Arch Pharm Res 2008 31 : 195 204.
52. Liang YJ, Shyu KG, Wang BW, Lai LP. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology 2008 110 : 182 90.
53. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002 106 : 1447 52.
54. Rosenson R, Brown AS. Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr Opin Lipidol 2002 13 : 625 31.
55. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004 292 : 1365 71.
56. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes The MIRACL Study: a randomized controlled trial. JAMA 2001 285 : 1711 8.
57. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 : 1495 503.
58. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 2004 292 : 1307 12.
59. Ridker PM, Rifai N, Pfeffer MA et al. For the cholesterol and recurrent events (CARE) investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 98 : 839 46.
60. Horne BD, Muhlestein JB, Carlquist JF et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000 36 : 1774 86.
61. Chan AW, Bhatt DL, Chew DP et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003 107 : 1750 62.
62. Ridker PM, Rifai N, Clearfield M et al. For the air force/texas coronary atherosclerosis prevention study investigators measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001 344 : 1959 67.
63. Atar S, Ye Y, Lin Y et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006 290 : 1960 8.
64. Masato E, Kozai T, Cosentino F et al. Statin prevents tissue factor expression in human endothelial cells. Role of Rho/Rho-kinase and AKT pathways. Circulation 2002 105 : 1756 9.
65. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004 172 : 2903 8.